Image

Pilot Study to Evaluate a Noninvasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With Conduction Disorders Following TAVI Implantation (IMPROVE Study)

Pilot Study to Evaluate a Noninvasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With Conduction Disorders Following TAVI Implantation (IMPROVE Study)

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Study to evaluate the efficacy and safety of a non-invasive electrocardiographic monitoring strategy associated with early discharge in patients with conduction disorder after transfemoral TAVI implantation, and its potential benefits compared to standard care.

Description

Study to evaluate the efficacy and safety of a non-invasive electrocardiographic monitoring strategy associated with early discharge in patients with conduction disorder after transfemoral TAVI implantation, and its potential benefits compared to standard care.

Eligibility

Inclusion Criteria:

All inclusion criteria must be met

  • Age ≥ 18 years and
  • Undergone successful transfemoral or transaortic TAVI for severe aortic stenosis and
  • Presence of at least one of the following conduction disorders and
  • Pre-procedural basal conduction disorder (e.g., right/left bundle branch block, bifascicular block, IVCD) with QRS between 120-160 msec.
  • De novo conduction disorder after TAVI (de novo bundle branch block) with QRS between 120-160 msec.
  • Clinical stability at 24 hours post-procedure and
  • Capacity to give informed consent.

Exclusion Criteria:

No exclusion criteria must be met

  • Immediate indication for permanent pacemaker following the procedure.
  • Persistent complete atrioventricular block.
  • QRS \>160 msec and/or PR prolongation.
  • Haemodynamic instability or complications of TAVI (major bleeding, stroke, decompensated heart failure) that contraindicate early discharge.
  • Technical or clinical impossibility of using the PhysioMem PM 1004G monitoring system.
  • Life expectancy \< 12 months due to non-cardiovascular comorbidity.
  • Refusal or inability to undergo outpatient follow-up.
  • Pregnant or breastfeeding.

Study details
    Severe Aortic Valve Stenosis
    Cardiovascular Diseases

NCT07456280

Hospital Universitari Vall d'Hebron Research Institute

20 October 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.